Medtech Startup StoneWise Raises $100 Million to Promote Use of AI in Drug Development

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: Geely Leads $141 Million Round for Tsinghua-Linked Robotics Startup; Intel Pivots to Custom Chips to Tap China’s Trillion-Yuan Computing Markets; Wingtech Demands Return of Nexperia Control After Dutch Freeze Pause

LATEST: AI Keeps China, U.S. From Decoupling Despite Trade Tensions, Insiders Say; Wingtech Demands Return of Nexperia Control After Dutch Freeze Pause; Intel Pivots to Custom Chips to Tap China’s Trillion-Yuan Computing Markets; Geely Leads $141 Million Round for Tsinghua-Linked Robotics Startup; China’s Giant Neutrino Detector Delivers First Results With Record Precision; China Unicom Taps Veteran Executive as Chairman to Navigate Telecom Transition; Chinese Self-Driving Firms Accelerate Into Middle East, Southeast Asia; Baidu Posts Record Revenue Decline as Ad Business Falters; Xiaomi’s EV, AI Units Post First Quarterly Profit; China’s Agricultural Drone Makers Pivot to Smarter Navigation as Size Race Ends; Alibaba Renames AI App to Stand Out in China’s Crowded Chatbot Market; Investors Flock to Chinese eVTOLs Chasing Regulatory Green Lights; Nexperia Headquarters Rachets Up Feud With China Unit With Salvo of Accusations; Robot-Maker Unitree Steps Closer to China IPO; Tencent Says Talks With Apple on WeChat Game Fees Are Advancing; Baidu Unveils Ambitious AI Chip Roadmap, Targeting 1 Million-Card Cluster by 2030; Tencent’s Profit Rises 19% on Overseas Gaming and AI-Powered Ad Surge; Caixin Summit: Design, Commercialization Key to China’s Low-Altitude Economy Taking Off, Industry Insider Says; China’s Robotics Revenue Soars as Industry Races to Crack Embodied AI; U.S. Formally Suspends Sweeping Export Control Rule for One Year After China Trade Talks

Ding Yi / Apr 13, 2021 07:04 PM / Business & Tech

StoneWise, a Chinese medtech startup which uses artificial intelligence (AI) technology to develop medicines, has completed its series B and series B+ funding rounds raising $100 million combined. The funding rounds come as the Covid-19 pandemic serves to highlight the role of AI and other cutting-edge technologies in diagnosing and treating diseases.

The series B round was led by Legend Capital, while the series B+ round was co-led by Greater Bay Area Homeland Development Fund and Lightspeed China. Other investors that joined the two rounds include Eastern Bell Capital, GL Ventures and Long Hill Capital, StoneWise said in a WeChat post on Monday.

Beijing-based StoneWise said it will use the proceeds from the two rounds to bankroll its global talent recruitment and widen the use of its AI technology in drug development.

Founded in 2018, StoneWise provides small molecule drug researchers with a smart drug development platform which is powered by technologies including AI algorithms, computational chemistry, pharmaceutical chemistry and computational biology, and enables the medicine development process to be more time-efficient and cost-effective, according to its website.

Contact reporter Ding Yi (yiding@caixin.com)

Share this article

Open WeChat and scan the QR code